Sandoz, > 98 %( HPLC ), poudre

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Sandoz 58-035 was used to induce simultaneous activation of unfolded protein response (UPR) and pattern recognition receptors (PRRs) in mouse peritoneal macrophages.³

Biochem/physiol Actions

Sandoz 58-035 inhibits the accumulation of cholesteryl esters and inhibits the esterification of cholesterol by 95% in arterial smooth muscle cells in culture.¹ It does not affect the triglyceride metabolism by the gut.²

Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle